ReviewCurrent drug discovery technologies2026
Recent Advancement in Drug Delivery Systems for the Treatment of Rheumatoid Arthritis.
Review in Current drug discovery technologies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Association of Micro- and Macro-Nutrient Patterns With the Risk of Rheumatoid Arthritis in Newly Diagnosed Cases: A Case-Control Study.Health science reports · 2026Article
- Pharmacological enhancement of anti-inflammatory drug efficacy through solid lipid nanoparticles in osteoarthritis and rheumatoid arthritis: a review.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that features chronic inflammation of the joints, destruction of the synovial tissue, and progressive disability. Traditional treatments with disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids are usually linked to systemic side effects and low therapeutic efficacy. Drug delivery systems based on nanotechnology have been presented as a valuable strategy for the improvement of drug bioavailability, toxicity decrease, and targeted treatment of RA. This review discusses the latest developments in nanotechnology-based drug delivery systems, such as liposomes, niosomes, nanoemulsions, solid lipid nanoparticles, ethosomes, and transferosomes, focusing specifically on transdermal drug delivery systems (TDDS). These nanocarriers provide long-term release of the drug, enhanced permeability, and enhanced therapeutic activity by more targeted delivery to inflamed areas. In addition, the combination of combination therapy, co-delivery approaches, and phototherapy has also exhibited synergistic effects to evade drug resistance and improve anti-inflammatory activity. Despite these developments, formulation stability, industrial manufacturing, and clinical translation remain critical challenges. Additional studies and clinical evidence are required to maximize nanotechnology-based therapies and integrate them into RA therapy.
Indexed as
Identifiers
40660434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.